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Abstract
Background: Malaria is one of the most important infectious diseases in the world. Although most
cases are found distributed in the tropical regions of Africa, Asia, Central and South Americas,
there is in Europe a significant increase in the number of imported cases in non-endemic countries,
in particular due to the higher mobility in today's society.
Methods: The prevalence of a possible asymptomatic infection with Plasmodium species was
assessed using Nucleic Acid Sequence Based Amplification (NASBA) assays on clinical samples
collected from 195 study cases with no clinical signs related to malaria and coming from sub-
Saharan African regions to Southern Italy. In addition, base-line demographic, clinical and socio-
economic information was collected from study participants who also underwent a full clinical
examination.
Results:  Sixty-two study subjects (31.8%) were found positive for Plasmodium  using a pan
Plasmodium specific NASBA which can detect all four Plasmodium species causing human disease,
based on the small subunit 18S rRNA gene (18S NASBA). Twenty-four samples (38%) of the 62
18S NASBA positive study cases were found positive with a Pfs25 mRNA NASBA, which is specific
for the detection of gametocytes of Plasmodium falciparum. A statistically significant association was
observed between 18S NASBA positivity and splenomegaly, hepatomegaly and leukopaenia and
country of origin.
Conclusion: This study showed that a substantial proportion of people originating from malaria
endemic countries harbor malaria parasites in their blood. If transmission conditions are available,
they could potentially be a reservoir. Thefore, health authorities should pay special attention to the
health of this potential risk group and aim to improve their health conditions.
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Background
Malaria is one of the most important infectious diseases in
the world. The World Health Organization estimates that
300–500 million cases of malaria infections, with 1–3
million deaths globally occurring each year, of which 95%
is caused by Plasmodium falciparum [1]. Although most
cases are found in the tropical regions of Africa, Asia, Cen-
tral, and South America, there is a significant increase in
the number of imported cases in Europe, in particular due
to the higher mobility of people in today's society [2].
Approximately 7,000 cases of imported malaria are
recorded in Europe annually [3]. Due to the misleading
symptoms related to initial malaria (i.e. fever and other
flu-like symptoms), prompt diagnosis and treatment are
of great importance. The Centers for Disease Control and
Prevention recommends that malaria should be consid-
ered in the differential diagnosis of febrile patients who
have traveled to a region where malaria is endemic and in
any patients who experience fevers of unknown origin
regardless of their travel history [2].
The current standard for diagnosis is the microscopic
examination of Giemsa-stained thick and thin blood
smears [4-8]. This procedure is not expensive and in prin-
ciple easy to perform, but becomes time-consuming in
particular in cases of mixed infection or low parasitaemia
and even with experienced microscopists examining the
blood slides, misdiagnosis may occur [4,8]. To aid malaria
diagnosis, other techniques have been developed, such as
immunochromatographic assays based on Plasmodium
antigen detection, but some of these tests perform poorly
in cases of low parasitemia [7,9,10] or, in contrast, lead to
a false positive diagnosis of malaria due to the persistence
of parasite antigen after adequate treatment [7,11]. Molec-
ular detection for Plasmodium with PCR has resulted in
increased sensitivity and species discrimination compared
to either microscopic or immunochromatographic diag-
nosis of malaria [12-18]. PCR based assays are sensitive
and can be converted to a quantitative format, if SYBR
green or molecular probes (e.g. a Taqman probe or a
molecular beacon) are used in real time format [19,20].
Alternatively, Nucleic Acid Sequence Based Amplification
(NASBA) technology can be applied, which has as advan-
tage above real-time PCR assays that it is fast to perform;
i.e. 60 minutes for NASBA compared to up to four hours
for real-time PCR [21,22]. NASBA assays, using molecular
beacons as detection probes, has been developed for dif-
ferent Plasmodium species and has shown to be very sensi-
tive with a detection limit of 20 parasites/ml blood
[22,23].
In the present study, NASBA using primers based on pan
species  Plasmodium-specific small sub-unit ribosomal
RNA gene sequences [24] was used to evaluate the preva-
lence of Plasmodium species in a population of migrants.
Furthermore, a gametocyte specific NASBA based on the
detection of the mRNA encoding for the P. falciparum
gametocyte specific Pfs25 gene [25] was employed to
detect mature sexual transmission stages in the same study
population.
Methods
Patient enrolment, information and sample collection, 
microscopy
One hundred and ninety five blood samples were col-
lected during the period April-September 2007 from study
cases who were temporarily guests in a refugee camp man-
aged by the Italian Red Cross, located in Borgo Mezza-
none (province of Foggia, Italy). All guests were orally
informed about the purpose of the study and invited to
participate. Subsequent recruitment was on voluntary
basis with no special inclusion criteria.
The study was reviewed and approved by the local Chief
of the Red Cross and written informed consent was
obtained from each study subject who was enrolled in the
study. All study procedures were in agreement with the
Helsinki Declaration (Edinburgh 2000). At enrolment, all
study participants were interviewed using a questionnaire
to obtain baseline demographic, clinical, and socioeco-
nomic information and to assess their previous exposure
to malaria. All enrolled subjects also received a full clinical
examination and were treated accordingly.
Anamnestic data
The mean age of the enrolled study subjects (n = 195) was
25.1 ± 5.7 years (range: 16–40 years) and the majority of
them (163, 83.6%) were men. Potential female study can-
didates could often not be recruited for the study because
they refused to undergo clinical examination. All enrolled
study participants came from in total 18 sub-Saharan Afri-
can countries (54.3% came from East Africa, 35.9% from
West Africa, 10.8% from Central Africa – Table 1) and
they were in Italy for a mean period of 54 days (range: 19–
121 days).
Participants were allocated into three groups on basis of
their reply to the questionnaire whether or not they had
malaria in the past. Those people acknowledging one or
more episodes of previous malaria in their country of ori-
gin were placed in group A: 58/195 (29.7%); subjects who
said that they did not previously had malaria were placed
in group B: 93/195 (47.7%); and individuals who could
not remember a previous malaria infection were group C:
44/195 (22.6%).
EDTA-anticoagulated blood samples were labeled and
temporarily stored for a maximum of 24 hours in a freezer
bag before transportation to the laboratory, where the
samples were stored a -80°C until processing for nucleicMalaria Journal 2009, 8:12 http://www.malariajournal.com/content/8/1/12
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acids isolation. Thin and thick blood smears were pre-
pared at the time of blood collection and stained with
10% Giemsa stain (pH 7.2).
Molecular analysis of blood samples
Nucleic acid extraction
Blood samples (100 μl) were mixed with 900 μl of gua-
nidium isothiocyanate lysis buffer before DNA and RNA
isolation [26]. Thirty μl of silica dioxide was added to each
sample after thorough mixing of the extraction mixture.
Subsequently, nucleic acids bound to silica were washed
twice with wash buffer (10 M GuSCN, 100 mM Tris-HCL
pH6.4), twice with 70% ethanol, and once with acetone.
Next, nucleic acids were eluted from the silica with 100 μl
water and stored at -20°C.
18S NASBA
Pan-Plasmodium specific NASBA targeting 18S rRNA [Gen-
Bank accession number M19172.1] of Plasmodium falci-
parum,  Plasmodium vivax,  Plasmodium malariae and
Plasmodium ovale was performed on an IQ5 Real-Time
analyzer (Bio-RAD) [23]. Amplification reactions were
performed using Nuclisens Basic Kit (bioMèrieux) follow-
ing the manufacturer's manual at a KCl concentration of
80 mM. The reaction mixture (5 μl) including primers and
molecular beacon was incubated with the RNA extract
(2.5 μl) at 65°C for two minutes and subsequently at
41°C for two minutes. 2.5 μl of Nuclisens enzyme mix-
ture (AMV-RT, RNase H and T7 RNA polymerase) was
added and amplification allowed for 90 minutes at 41°C.
The forward primer was: 5' TCAGATACCGTCGTAATCTTA
3' (nucleotides1066 to 1086); the reverse primer was: 5'-
AATTCTAATACGACTCACTATAGGGAGAAGGAACTT-
TCTCGCTTGCGCGAA-3' (T7 promoter sequence, linker
and nucleotides 1216 to 1235); the Pf18S molecular bea-
con was: 5'-FAM- CGATCG-GAGAAATCAAAGTCTTT-
GGG-CGATCG-DABSYL-3' (molecular beacon stem of 6
paired nucleotides and nucleotides 1182 to 1201). Time
to positivity (TTP), i.e. the time point during amplifica-
tion at which the number of target amplicons detected
became higher than the mean for two negative controls
plus 20 standard deviations, was calculated. Standard ring
stage parasite dilution series were used as positive con-
trols. A sample containing only water and reactions mix-
ture was used as negative control. The analysis of samples
and appropriate positive and negative controls were per-
formed in duplicate.
Pfs25 NASBA
18S rRNA NASBA positive samples were also analysed for
gametocyte specific Pfs25 mRNA QT-NASBA [25]. Briefly,
real-time QT-NASBA for Pfs25 mRNA [GenBank accession
number AF193769.1] was performed on a NucliSens
EasyQ analyzer (bioMèrieux) using the Nuclisens BasicKit
for amplification according to the manufacturer's manual
at a KCl concentration of 80 mM and the same conditions
of Real-Time 18S QT_NASBA.
The forward primer was 5'-GACTGTAAATAAACCATGT-
GGAGA-3' (nucleotides 204 to 227); the reverse primer
was 5'-AATTCTAATACGA CTCACTATAGGGAGAAGG-
CATTTACCGTTACCACAAGTTA-3' (T7 promoter
Table 1: Summary of country of origin, number of cases included, 18S NASBA positive cases and gametocyte carriers
Country Total number of cases included in 
the study
Total number of 18S NASBA positive 
cases from the respective country
Gametocyte carriers as assessed by 
Pfs25 NASBA
Ivory Coast – West Africa 14 3 1
Togo – West Africa 3
Guinea – West Africa 8 2
Somalia – East Africa 37 11 1
Ethiopia – East Africa 1
Eritrea – East Africa 63 18 2
Ghana – West Africa 20 6 3
Nigeria – Central Africa 17 8 1
Burkina Faso – West Africa 7 1 1
Mali – West Africa 9 6 3
Cameroon – Central Africa 1
Liberia – West Africa 3 2 1
Gambia – West Africa 4 1
Chad – Central Africa 2
Senegal – West Africa 2 1
Sudan – East Africa 3 2
Congo – Central Africa 1 1
Total 195 62 13Malaria Journal 2009, 8:12 http://www.malariajournal.com/content/8/1/12
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sequence, linker and nucleotides 338–359); the PfS25
molecular beacon was 5'-Texas-Red-CGATCG-CCCGTT-
TCATACGCTTGTAA-CGATCG-DABSYL-3' (molecular
beacon stem of six paired nucleotides and nucleotides
259–278). Time to positivity was calculated, i.e. the time
point during amplification at which the fluorescence
detecting target amplicons exceeded the mean fluores-
cence of two negative controls plus 20 standard devia-
tions. Standard gametocytes dilution series were used as
positive controls. The samples and the positive controls
were performed in duplicate.
Statistical analysis
In order to value the statistical association between his-
tory of malaria and signs and symptoms (i.e. splenomeg-
aly, hepatomegaly, jaundice, urticaria, rales, leukopaenia,
normocytic haemolytic anaemia, transaminase level) con-
tingency double-entry tables were used and Odds Ratio
and relative 95% Confidence Intervals and X2 value were
calculated. A p value of < 0.05 was considered statistically
significant.
In order to evaluate the statistical association between 18S
NASBA and the following variables: sex, regions of origin
(West Africa, Central Africa, East Africa), previous epi-
sodes of clinical malaria as well as current clinical signs
(i.e. splenomegaly, hepatomegaly, jaundice, urticaria,
rales, leukopaenia, normocytic haemolytic anaemia,
transaminase level) contingency double-entry tables were
used and Odds Ratio and relative 95% Confidence Inter-
vals and X2 value were calculated. The t-Student's method
was employed for the comparative evaluation of quantita-
tive variables (continuous variables- i.e: age). A p value of
< 0.05 was considered statistically significant. In order to
value the potential confounding effect of considered vari-
ables (sex, age, regions of origins, history of malaria, cur-
rent clinical symptoms and signs) on 18S NASBA
positivity logistic regression model was performed.
Results
Clinical features
All examined study cases did not present at the time of
examination or in the previous two months, the malaria
paroxysm- characterized by high fever, chills and rigor.
On physical examination 98/195 (50.2%) cases were
found to have splenomegaly and tender hepatomegaly;
50/98 (51.0%) were in group A, 27/98 (27.6%) in group
B and 21/98 (21.4%) in group C. Splenomegaly as well as
hepatomegaly was significantly associated with group A
(splenomegaly: OR 2.71, 95%CI = 1.36–5.48; χ2 = 9.53, p
< 0.05; hepatomegaly: OR = 3.01, 95%CI = 1.16–7.76; χ2
= 6.8, p < 0.05). However, an inverse relationship was
found between spenomegaly and group B (OR = 0.48,
95%CI = 0.26–0.89; χ2 = 6.28, p < 0.05).
Other physical findings that have been observed are: jaun-
dice 25/195 (12.8%), scleral icterus 61/195 (31.3%), urti-
caria 37/195 (19.9%). Auscultation of the chest revealed
scattered rales in about 25% of subjects. Cardiac examina-
tion was generally normal except for tachycardia in about
10% of patients.
Some abnormalities in routine laboratory tests were
found in some study participants. Normocytic haemolytic
anaemia presented in 61/195 (31.3%) of the cases; leuko-
paenia due to a decrease in granulocytes and lymphocytes
was present in 96/195 (49.2%) and these cases also pre-
sented with eosinophilia in the presence of urticaria. Leu-
kopaenia was significant associated with group A (OR =
2.19, 95%CI = 1.11–4.36; χ2 = 6.05, p < 0.05). Liver func-
tion tests revealed elevated transaminase levels in 32/195
(16.4%) of the cases and a mild to moderate increase in
bilirubin (mostly indirect) in 86/195 (44.1%) of the study
subjects; this variable resulted inversely associated with
group C (OR 0.09, 95%CI = 0.002–50.56; χ2 = 8.28, p <
0.05).
Serological markers for HIV were found positive in 0.8%
of the enrolled cases, for HIV/HBV in 0.4% of the study
individuals, for HIV/HCV in 0.6% of the cases, for HBV in
9.7% of the subjects and for HCV in 1.1% of the cases.
Luetic infection was present in 6.4% of examined study
subjects.
NASBA
In total, 62 study participants (31.7%) were found posi-
tive for the presence of Plasmodium  nucleic acids as
revealed with the applied NASBA technique. These cases
were distributed as follows: 18/58 (31.0%) belong to
Group A, 28/93 (30.1%) belong to Group B and 16/44
(36.4%) belong to Group C. The distribution according to
country of origin is presented in Table 1.
Microscopy confirmed the positive NASBA results in 14
cases and these cases were distributed as follows: six
belonged to Group A, six belonged to Group B and two
belonged to Group C. Quantification of parasitaemia was
not available.
Plasmodium falciparum was observed in 13 samples and
one sample was identified as being P. ovale. Thirteen cases
(21%) of this Plasmodium18S rRNA positive population
were also found positive with a Pfs25 mRNA NASBA,
which is specific for the detection of gametocytes of P. fal-
ciparum. Four cases positive for gametocytes were con-
firmed by microscopy.
No significant association (p > 0.05) was found between
18S NASBA positivity and sex, age, history of malaria and
region of origins.Malaria Journal 2009, 8:12 http://www.malariajournal.com/content/8/1/12
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A statistically significant association was found between
18S NASBA positivity and splenomegaly (χ2 = 89.97, p <
0.001), hepatomegaly (χ2 = 79.54, p < 0.001) and leuko-
penia (χ2 = 89.97, p < 0.001): in all subjects who were
found positive with the 18S NASBA, splenomegaly,
hepatomegaly and leukopaenia were reported. The rela-
tive OR values were not computable. No other signs and
symptoms was associated with 18S NASBA positivity.
By logistic regression model, a significant association was
found between 18S NASBA and country of origin (p <
0.05). In particular, a high probability to be positive at
18S NASBA was observed in people coming from West
Africa (OR: 33.8; 95%CI: 1.1–1085.5), Central Africa
(OR: 56.7; 95%CI: 1.2–2598.9) and East Africa (OR:
235.6; 95%CI: 3.9–14290.9). By using the same regres-
sion model, a significant inverse association was found
between increased transaminase levels and 18S NASBA
positivity (OR: 0.14; 95%CI: 0.03–0.64; p < 0.05) so that
people with increased transaminase levels had a lower
probability to be positive at 18S NASBA. By the model, no
significant associations (p < 0.05) were found between
18S NASBA positivity and sex, age, history of malaria,
other signs and symptoms (splenomegaly, hepatomegaly,
jaundice, urticaria, rales, leukopaenia, normocytic
haemolytic anaemia).
Discussion
In many countries, the increase in imported malaria cases
from different countries is due to the increasing number
of people traveling to and from endemic areas, without
taking appropriate prophylaxis or immigration from low
income countries [27,28]. In the case of returning non-
immune travelers, malaria infection is often very obvious
with severe disease and sometimes fatal outcome. In con-
trast, people from disease endemic countries may have
acquired semi-immunity, resulting in less serious to none
manifestations of disease, as was also shown in Spain
[28], and recently also in Italy [29]. However, a propor-
tion of this population may develop disease over time due
to weaning immunity and/or contribute to possible trans-
mission. In general, people originating from malaria
endemic countries may have sub-microscopic levels of
parasitaemia, but may feel not ill at all or present typical
features of malaria. This is also reflected in the present
study. Although many study participants could not recall
having had malaria in the past, when being interviewed,
there was no difference between the levels of infection
between these participants and those who could recall an
episode of malaria. In a substantial proportion of the
examined population low levels of Plasmodium parasites
were found with the applied NASBA technology. Further-
more, clinical examination revealed a statistically signifi-
cant association between splenomegaly and 18S NASBA
positivity. Malarial splenomegaly is believed to be a con-
sequence of an immunological dysfunction due to recur-
rent episodes of malaria [30,31]. It is generally considered
that prolonged exposure to malarial parasites (5–10
years) is needed to develop splenomegaly, this response is
based on a overproduction of polyclonal IgM antibodies,
leading to accumulation of high molecular-weight immu-
nocomplexes and complement consumption. Long-term
purification of immunocomplexes induces progressive
hyperplasia of the spleen [32,33]. Patients usually present
hypersplenism, and may have anaemia, leukopaenia,
thrombopaenia and even haemolytic crises, depending on
the severity [34]. A significant inverse association was
found between increased transaminase levels and 18S
NASBA positivity; i.e. people with increased transaminase
levels had a lower probability to be positive at 18S
NASBA. However, the high prevalence of patients with
viral hepatitis infections observed in this study could also
be the consequence of other diseases.
It was further noted in the present study that 21% of the
Plasmodium18S rRNA positive population was also found
positive with a Pfs25 mRNA NASBA, which indicates that
these cases harbour gametocytes and may thus contribute
to possible malaria transmission, even if the number of
gametocytes is very low.
In Italy, malaria was eradicated after a campaign launched
in 1947 just at the end of World War II. The campaign was
carried out by indoor treatment with DDT; houses, sta-
bles, shelters and all rural structures were treated into the
mid-1950s and also later in some endemic regions, such
as Sardinia. Due to the persistence of sporadic malaria
cases in some areas [35,36], the WHO declared Italy free
of malaria only in 1970. In order to circumvent the poten-
tial reintroduction of malaria, a strict surveillance system
was set up, which is still in place and governed by the Min-
istry of Health and the Istituto Superiore di Sanità (ISS,
Rome, Italy), following WHO guidelines [37].
Over the last two decades, with the exception of one auto-
chthonous case registered in 1997 in a rural area of the
province of Grosseto (Tuscany), which was followed by
four more cases (i.e. a cryptic case by P. falciparum in 2003
[38], two cases due to organ transplantation in 2004 [39]
and a transfusional case in 2005, all cases of malaria have
been imported [40-42]). Until to 1999 the number of
imported cases of malaria arose constantly, while from
2002 to 2006 a decrease between 1% and 7% per year has
been registered [37] in both immigrant (-9%) and among
Italian citizens(-28%). Most of the cases registered from
2002–2006 were among people from Africa (88.4%),
and, in particular, from Nigeria (26%), Ghana (17%),
Senegal (17%), Costa d'Ivoire (12%), and Burkina Faso
(6.7%). Furthermore, additional cases were reported in
2000 [43] and in 2002 [44] in Chinese immigrants whoMalaria Journal 2009, 8:12 http://www.malariajournal.com/content/8/1/12
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traveled to Italy via Africa. Plasmodium falciparum was con-
firmed to be the most prevalent species imported in
southern Europe [27,28,37]; in Italy, this species is
responsible for 89% of the infection, P. vivax for 7.7%, P.
ovale and P. malariae, 6% and 1.5%, respectively [29,37].
In addition, mixed Plasmodium infections have also been
reported in Italy, with 58% of all these cases reported from
a single town, Verona [29].
The distribution and density of the three potential vectors
of malaria in Italy (Anopheles labranchiae, Anopheles super-
pictus and Anopheles sacharovi) are also under strict surveil-
lance by Istituto Superiore di Sanità (ISS). Anopheles
labranchiae  is present in several areas of Central and
Southern Italy and in some regions (Tuscany, Calabria,
Puglia, Sardinia and Sicily) high density have been regis-
tered [41]. The density of An. superpictus is lower and
breeding sites are restricted to Calabria coasts and Sicily
while although An. sacharovi has not registered since over
30 years, its presence in low density cannot be excluded in
Apulia and northern Sardinia regions [37].
The combination of the presence of potential vectors and
gametocyte carriers may pose a risk for re-introduction of
malaria in the country. However, it should be noted that
certain climatological and ecological prerequisites should
probably be also met before the disease is really reintro-
duced [37].
Conclusion
This study showed that a substantial proportion of people
originating from malaria endemic countries and not
showing clinical signs of malaria harbor Plasmodium para-
sites in their blood (i.e. 32% of positivity to Plasmodium
spp., 21% of population harboring P. falciparum gameto-
cytes). If transmission prerequisites (e.g. vector, suscepti-
ble population and climatological conditions) prevail
they could potential be a reservoir. Therefore, health
authorities should pay special attention to the health of
this potential risk group and aim to improve their health
conditions.
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